Skip to main content
SpringerLink
Log in
Book cover

Prostate Cancer Diagnosis pp 363–372Cite as

Future Directions in Prostate Cancer Diagnosis

  • Chapter
  • First Online:

  • 1525 Accesses

Part of the book series: Current Clinical Urology ((CCU))

Abstract

Since Hugh Hampton Young described his series of 111 prostate cancer patients in 1909 (Young, Ann Surg 50(6):1144–233, 1909), much progress has been made in the diagnosis of prostate cancer. Many of Dr. Young’s patients were diagnosed when symptoms of advanced prostate cancer developed, and many died of their disease. A century later, 80 % of prostate cancers are diagnosed while still localized (Siegel et al. CA Cancer J Clin 61(4):212–36, 2011). The prostate cancer mortality rate now stands at its lowest point in more than 70 years after falling for 14 consecutive years despite the aging of the population (Siegel et al. CA Cancer J Clin 61(4):212–36, 2011). While many factors have contributed to these trends, earlier diagnosis has played a large role in improving outcomes.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Young HH. XV. Cancer of the prostate: a clinical, pathological and post-operative analysis of 111 cases. Ann Surg. 1909;50(6):1144–233.

    Article  PubMed  CAS  Google Scholar 

  2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.

    Article  PubMed  Google Scholar 

  3. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909–16.

    Article  PubMed  CAS  Google Scholar 

  4. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003;97(6):1528–40.

    Article  PubMed  Google Scholar 

  5. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001–testing for early lung cancer detection. CA Cancer J Clin. 2001;51(1):38–75. quiz 77–80.

    Article  PubMed  CAS  Google Scholar 

  6. American Urological Association (AUA): Prostate-specific antigen (PSA) best practice policy. Oncology (Williston Park) 14(2):267–272, 277–268, 280 passim.

    Google Scholar 

  7. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006;56(1):11–25. quiz 49–50.

    Article  PubMed  Google Scholar 

  8. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8.

    Article  PubMed  Google Scholar 

  9. Andriole GL, Grubb 3rd RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;260(13):1310–9.

    Article  Google Scholar 

  10. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70–98.

    Article  PubMed  Google Scholar 

  11. Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182(5):2232–41.

    Article  PubMed  CAS  Google Scholar 

  12. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708–17.

    Article  PubMed  CAS  Google Scholar 

  13. Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case–control study. BMJ. 2010;341:c4521.

    Article  PubMed  Google Scholar 

  14. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359(20):2143–53.

    Article  PubMed  CAS  Google Scholar 

  15. Pomerantz MM, Freedman ML. Genetics of prostate cancer risk. Mt Sinai J Med. 2010;77(6):643–54.

    Article  PubMed  Google Scholar 

  16. Kote-Jarai Z, Olama AA, Giles GG, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet. 2011;43(8):785–91.

    Article  PubMed  CAS  Google Scholar 

  17. Eeles RA, Kote-Jarai Z, Al Olama AA. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009;41(10):1116–21.

    Article  PubMed  CAS  Google Scholar 

  18. Schumacher FR, Berndt SI, Siddiq A, et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011;20(19):3867–75.

    Article  PubMed  CAS  Google Scholar 

  19. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(3):316–21.

    Article  PubMed  CAS  Google Scholar 

  20. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38(6):652–8.

    Article  PubMed  CAS  Google Scholar 

  21. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet. 2009;41(10):1122–6.

    Article  PubMed  CAS  Google Scholar 

  22. Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007;39(5):631–7.

    Article  PubMed  CAS  Google Scholar 

  23. Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet. 2008;40(3):281–3.

    Article  PubMed  CAS  Google Scholar 

  24. Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007;39(8):977–83.

    Article  PubMed  CAS  Google Scholar 

  25. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008;40(3):310–5.

    Article  PubMed  CAS  Google Scholar 

  26. Yeager M, Chatterjee N, Ciampa J, et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet. 2009;41(10):1055–7.

    Article  PubMed  CAS  Google Scholar 

  27. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39(5):645–9.

    Article  PubMed  CAS  Google Scholar 

  28. Zheng SL, Stevens VL, Wiklund F, et al. Two independent prostate cancer risk-associated loci at 11q13. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1815–20.

    Article  PubMed  CAS  Google Scholar 

  29. Sun J, Zheng SL, Wiklund F, et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res. 2009;69(1):10–5.

    Article  PubMed  CAS  Google Scholar 

  30. Sun J, Zheng SL, Wiklund F, et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet. 2008;40(10):1153–5.

    Article  PubMed  CAS  Google Scholar 

  31. Takata R, Akamatsu S, Kubo M, et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet. 2010;42(9):751–4.

    Article  PubMed  CAS  Google Scholar 

  32. Hsu FC, Sun J, Wiklund F, et al. A novel prostate cancer susceptibility locus at 19q13. Cancer Res. 2009;69(7):2720–3.

    Article  PubMed  CAS  Google Scholar 

  33. Al Olama AA, Kote-Jarai Z, Giles GG, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet. 2009;41(10):1058–60.

    Article  PubMed  CAS  Google Scholar 

  34. Xu J, Zheng SL, Isaacs SD, et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci USA. 2010;107(5):2136–40.

    Article  PubMed  CAS  Google Scholar 

  35. Duggan D, Zheng SL, Knowlton M, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst. 2007;99(24):1836–44.

    Article  PubMed  CAS  Google Scholar 

  36. Liu F, Hsing AW, Wang X, et al. A systematic confirmation study of reported prostate cancer risk-associated SNPs in Chinese men. Cancer Sci. 2011;102(10):1916–20.

    Article  PubMed  CAS  Google Scholar 

  37. Macinnis RJ, Antoniou AC, Eeles RA, et al. A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet Epidemiol. 2011;35(6):549–56.

    PubMed  Google Scholar 

  38. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4(2):143–53.

    Article  PubMed  CAS  Google Scholar 

  39. Jeronimo C, Bastian PJ, Bjartell A, et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol. 2011;60(4):753–66.

    Article  PubMed  CAS  Google Scholar 

  40. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell. 2007;128(4):635–8.

    Article  PubMed  CAS  Google Scholar 

  41. Lopez-Serra L, Esteller M. Proteins that bind methylated DNA and human cancer: reading the wrong words. Br J Cancer. 2008;98(12):1881–5.

    Article  PubMed  CAS  Google Scholar 

  42. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148–59.

    Article  PubMed  CAS  Google Scholar 

  43. Woodson K, Gillespie J, Hanson J, et al. Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens. Prostate. 2004;60(1):25–31.

    Article  PubMed  CAS  Google Scholar 

  44. Powell IJ, Dey J, Dudley A, et al. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urology. 2002;59(6):907–12.

    Article  PubMed  Google Scholar 

  45. Hamilton RJ, Aronson WJ, Presti Jr JC, et al. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer. 2007;110(10):2202–9.

    Article  PubMed  CAS  Google Scholar 

  46. Woodson K, Hayes R, Wideroff L, Villaruz L, Tangrea J. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate. 2003;55(3):199–205.

    Article  PubMed  CAS  Google Scholar 

  47. Enokida H, Shiina H, Urakami S, et al. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer. 2005;116(2):174–81.

    Article  PubMed  CAS  Google Scholar 

  48. Ellinger J, Haan K, Heukamp LC, et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate. 2008;68(1):42–9.

    Article  PubMed  CAS  Google Scholar 

  49. Roupret M, Hupertan V, Yates DR, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res. 2007;13(6):1720–5.

    Article  PubMed  CAS  Google Scholar 

  50. Hoque MO, Topaloglu O, Begum S, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol. 2005;23(27):6569–75.

    Article  PubMed  CAS  Google Scholar 

  51. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693–705.

    Article  PubMed  CAS  Google Scholar 

  52. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435(7046):1262–6.

    Article  PubMed  CAS  Google Scholar 

  53. Ellinger J, Kahl P, von der Gathen J, et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate. 2010;70(1):61–9.

    Article  PubMed  CAS  Google Scholar 

  54. Catto JW, Alcaraz A, Bjartell AS, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59(5):671–81.

    Article  PubMed  CAS  Google Scholar 

  55. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol. 2009;41(1):87–95.

    Article  PubMed  CAS  Google Scholar 

  56. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67(13):6130–5.

    Article  PubMed  CAS  Google Scholar 

  57. Schaefer A, Jung M, Mollenkopf HJ, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126(5):1166–76.

    PubMed  CAS  Google Scholar 

  58. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–8.

    Article  PubMed  CAS  Google Scholar 

  59. Carlsson J, Davidsson S, Helenius G, et al. A miRNA expression signature that separates between normal and malignant prostate tissues. Cancer Cell Int. 2011;11(1):14.

    Article  PubMed  CAS  Google Scholar 

  60. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8.

    Article  PubMed  CAS  Google Scholar 

  61. Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin. 2009;59(6):379–90.

    Article  PubMed  Google Scholar 

  62. Villers A, Lemaitre L, Haffner J, Puech P. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance. Curr Opin Urol. 2009;19(3):274–82.

    Article  PubMed  Google Scholar 

  63. Puech P, Potiron E, Lemaitre L, et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology. 2009;74(5):1094–9.

    Article  PubMed  Google Scholar 

  64. Villers A, McNeal JE, Redwine EA, Freiha FS, Stamey TA. The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J Urol. 1989;142(3):763–8.

    PubMed  CAS  Google Scholar 

  65. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program. Oncologist. 2007;12(1):20–37.

    Article  PubMed  Google Scholar 

  66. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302(11):1202–9.

    Article  PubMed  CAS  Google Scholar 

  67. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9.

    Article  PubMed  Google Scholar 

  68. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235–9.

    Article  PubMed  CAS  Google Scholar 

  69. Stott SL, Lee RJ, Nagrath S, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010;2(25):25ra23.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, 9500 Euclid Ave., Desk Q10-1, Cleveland, OH, 44195, USA

    Joseph C. Klink M.D. & Eric Klein M.D.

Authors
  1. Joseph C. Klink M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Klein M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Klein M.D. .

Editor information

Editors and Affiliations

  1. Cleveland Clinic, Cleveland Clinic Lerner College of Medic, Department of Regional Urology, at Case Western Reserve, Cleveland, 44195, Ohio, USA

    J. Stephen Jones

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Klink, J.C., Klein, E. (2013). Future Directions in Prostate Cancer Diagnosis. In: Jones, J. (eds) Prostate Cancer Diagnosis. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-188-2_26

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-188-2_26

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-187-5

  • Online ISBN: 978-1-62703-188-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation